Evidence map›Paper›PMID 38069279›Full record

ReviewInternational journal of molecular sciences2023

Multifunctional Nanoplatform for NIR-II Imaging-Guided Synergistic Oncotherapy.

Qingluo Wang, Guoyu Xia, Jianmin Li, Longlong Yuan, Shujie Yu, Dingyang Li, Nan Yang, Zhongxiong Fan, Jinyao Li

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Organic Semiconducting Polymers for Cancer Sonodynamic Immunotherapy.Polymer science & technology (Washington, D.C.) · 2026
    Review
  2. Review
  3. Review
  4. Mini Review On: The Roles of DNA Nanomaterials in Phototherapy.International journal of nanomedicine · 2025
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Qingluo WangXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology & Institute of Materia Medica, Xinjiang University, Urumqi 830017, China.
Guoyu XiaXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology & Institute of Materia Medica, Xinjiang University, Urumqi 830017, China.
Jianmin LiXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology & Institute of Materia Medica, Xinjiang University, Urumqi 830017, China.
Longlong YuanXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology & Institute of Materia Medica, Xinjiang University, Urumqi 830017, China.
Shujie YuXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology & Institute of Materia Medica, Xinjiang University, Urumqi 830017, China.
Dingyang LiXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology & Institute of Materia Medica, Xinjiang University, Urumqi 830017, China.
Nan YangXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology & Institute of Materia Medica, Xinjiang University, Urumqi 830017, China.
Zhongxiong FanXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology & Institute of Materia Medica, Xinjiang University, Urumqi 830017, China.ORCID 0000-0001-5751-9530
Jinyao LiXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology & Institute of Materia Medica, Xinjiang University, Urumqi 830017, China.ORCID 0000-0002-3295-6096
Xinjiang University · CN

Funding

Opening Project of Xinjiang Uyghur drug Key Laboratory wysys-2023-01the Autonomous Region universities basic research funds research projects-cultivation projects XJEDU2023P108the Key research and development program in Xinjiang Uygur Autonomous Region 2022B02058the Xinjiang Uygur Autonomous Region Tianchi Talent Introduction Program-Young Doctor 51052300514
6 · The paper itself

Abstract

Tumors are a major public health issue of concern to humans, seriously threatening the safety of people's lives and property. With the increasing demand for early and accurate diagnosis and efficient treatment of tumors, noninvasive optical imaging (including fluorescence imaging and photoacoustic imaging) and tumor synergistic therapies (phototherapy synergistic with chemotherapy, phototherapy synergistic with immunotherapy, etc.) have received increasing attention. In particular, light in the near-infrared second region (NIR-II) has triggered great research interest due to its penetration depth, minimal tissue autofluorescence, and reduced tissue absorption and scattering. Nanomaterials with many advantages, such as high brightness, great photostability, tunable photophysical properties, and excellent biosafety offer unlimited possibilities and are being investigated for NIR-II tumor imaging-guided synergistic oncotherapy. In recent years, many researchers have tried various approaches to investigate nanomaterials, including gold nanomaterials, two-dimensional materials, metal sulfide oxides, polymers, carbon nanomaterials, NIR-II dyes, and other nanomaterials for tumor diagnostic and therapeutic integrated nanoplatform construction. In this paper, the application of multifunctional nanomaterials in tumor NIR-II imaging and collaborative therapy in the past three years is briefly reviewed, and the current research status is summarized and prospected, with a view to contributing to future tumor therapy.

Indexed as

NanoparticlesNanostructuresNeoplasmsHumansOptical ImagingPhototherapyPolymersTheranostic NanomedicinePolymersintegration of diagnosis and treatmentnanomaterialssecond near-infrared windowssynergistic oncotherapytumor imaging

Identifiers

PMID38069279
PMCPMC10707236
OpenAlexW4389132488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.